4-hydrazino-2-thiophen-2-yl-thieno[2,3-d]pyrimidine | 56843-86-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 4-hydrazino-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
• 英文别名: (2-Thiophen-2-ylthieno[2,3-d]pyrimidin-4-yl)hydrazine
• CAS: 56843-86-8
• 化学式: C₁₀H₈N₄S₂
• 分子量: 248.332
• InChiKey: XKTAYYJMTDHEQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-hydrazino-2-thiophen-2-yl-thieno[2,3-d]pyrimidine 在 mercury(II) oxide 作用下， 以 水 为溶剂， 生成 2-(2-Thienyl)-thieno<2.3-d>pyrimidin
  参考文献：
  名称：

  Bourguignon,J. et al., Bulletin de la Societe Chimique de France, 1975, p. 815 - 819

  摘要：

  DOI：
• 作为产物：
  描述：

  Ethyliden-cyanessigsaeure-methylester 在 哌啶 、 盐酸 、 sulfur 、 一水合肼 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 生成 4-hydrazino-2-thiophen-2-yl-thieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

  摘要：

  Inactivation of the NF-kappa B signaling pathway by inhibition of IKK beta is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKb inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-alpha, which are well-known inflammatory responses generated by activated NF-kappa B. However, no inhibitory activity against IKK beta was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 mu M. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.058

文献信息

• BOURGUIGNON J.; GOUGEON E.; QUEGUINER G.; PASTOUR P., BULL. SOC. CHIM. FRANCE <BSCF-AS>, 1975, NO 3-4, PART 2, 815-819
  作者：BOURGUIGNON J.、 GOUGEON E.、 QUEGUINER G.、 PASTOUR P.

  DOI：——

  日期：——
• Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors
  作者：Chun-Ho Park、Chulho Lee、Jee Sun Yang、Bo-Young Joe、Kwangwoo Chun、Hyuntae Kim、Hye Yun Kim、Jong Soon Kang、Jangik I. Lee、Myung-Hwa Kim、Gyoonhee Han

  DOI：10.1016/j.bmcl.2014.04.058

  日期：2014.6

  Inactivation of the NF-kappa B signaling pathway by inhibition of IKK beta is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKb inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-alpha, which are well-known inflammatory responses generated by activated NF-kappa B. However, no inhibitory activity against IKK beta was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 mu M. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML. (C) 2014 Elsevier Ltd. All rights reserved.
• Bourguignon,J. et al., Bulletin de la Societe Chimique de France, 1975, p. 815 - 819
  作者：Bourguignon,J. et al.

  DOI：——

  日期：——